In this study, our findings revealed LAMC2 as a key oncogenic molecule in iCCA patients via LAMC2/BiP/EGFR axis and as a potential indicator in suggesting iCCA patients for available EGFR TKIs therapies. The gene discussed is EGFR; the disease is infantile convulsions and choreoathetosis.